Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine‐microemulsion
- 1 February 2002
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 16 (1) , 48-54
Abstract
Treatment of end‐stage renal disease (ESRD) is evaluated by survival, quality of life (QOL) and cost‐effectiveness. Little is known about the influence of immunosuppressive agents on global and disease‐specific QOL in kidney recipients.In winter 1997/98 (t0) as well as in winter 1998/99 (t1), all kidney recipients of our University were asked to participate in a QOL study. The psychodiagnostic approach combined a global QOL‐measure (SF‐36 Health Survey) and a disease‐specific questionnaire (ESRD‐SCLTM, Nephron 1999). Inclusion criteria for the final analysis were (a) participation in both surveys and (b) eligibility after the matching procedure: patients with tacrolimus‐based immunosuppressive regimen were matched to patients with cyclosporin‐microemulsion (CsA‐ME)‐based immunosuppressive‐regimen as to age, gender and duration of graft function. Group data were compared by performing a two‐variate (`immunosuppression', `time') analysis of variance. Both groups consisted of 63 patients. Analysis of QOL revealed statistically significant advantages for the tacrolimus treated patients concerning global (SF‐36 `Physical Component Summary') as well as disease‐specific QOL (ESRD‐SCLTM`Global Severity Index'; both p < 0.05). In detail, these results were due to statistically significant better QOL in tacrolimus treated patients as to the SF‐36 subscales `Physical Functioning' and `General Health' (p < 0.05) and the ESRD‐SCLTMsubscales `Limited Physical Capacity' (p < 0.05), `Cardial and Renal Dysfunction' (p < 0.01) and `Increased Growth of Gum and Hair' (p < 0.001). The factor `time' did not contribute statistically significant to explanation of variance.In terms of QOL in kidney recipients, tacrolimus is superior to CsA‐ME. Tacrolimus improves disease‐specific QOL and also shows slight advantages concerning global QOL compared with CsA‐ME. To record differentiated aspects of QOL in kidney recipients, the diagnostic approach should include a global QOL measure completed by a sensitive disease‐specific instrument.Keywords
This publication has 30 references indexed in Scilit:
- Survival of patients who have been on a waiting list for renal transplantationNephrology Dialysis Transplantation, 2000
- DOES TRANSPLANTATION PRODUCE QUALITY OF LIFE BENEFITS?Transplantation, 1997
- THE RELATIVE EFFECTS OF FK506 AND CYCLOSPORINE ON SHORT- AND LONG-TERM KIDNEY GRAFT SURVIVAL1,2,3Transplantation, 1995
- Mode of Action of Tacrolimus (FK506): Molecular and Cellular MechanismsTherapeutic Drug Monitoring, 1995
- Cost-Effectiveness Studies of Renal TransplantationInternational Journal of Technology Assessment in Health Care, 1995
- Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejectionThe Lancet, 1994
- Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients1993
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Prognostically controlled comparison of dialysis and renal transplantationKidney International, 1984
- Survival with Dialysis and Transplantation in Patients with End-Stage Renal DiseaseNew England Journal of Medicine, 1983